Bell Investment Advisors, Inc Mirati Therapeutics, Inc. Transaction History

Bell Investment Advisors, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $377 - $561	9 New	9 $0
Q2 2023 Aug 09, 2023	SELL	$36.13 - $49.49 $433 - $593	-12 Reduced 50.0%	12 $0
Q1 2023 May 10, 2023	BUY	$36.54 - $54.26 $876 - $1,302	24 New	24 $0
Q3 2022 Nov 09, 2022	BUY	$59.5 - $86.7 $416 - $606	7 Added 87.5%	15 $1,000
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $313 - $709	8 New	8 $1,000

Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $1,056 - $1,522	-8 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $1,057 - $1,419	8 New	8 $1,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Bell Investment Advisors, Inc with notifications on news.